Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Results from a Phase 1 Dose Escalation and Expansion Study

被引：12

作者：

DiNardo, Courtney D. ^{[1
]}

Watts, Justin M. ^{[2
]}

Stein, Eytan M. ^{[3
]}

De Botton, Stephane ^{[4
]}

Fathi, Amir T. ^{[5
]}

Prince, Gabrielle T. ^{[6
]}

Stein, Anthony S. ^{[7
]}

Foran, James M. ^{[8
]}

Stone, Richard M. ^{[9
]}

Patel, Prapti A. ^{[10
]}

Tallman, Martin S. ^{[3
]}

Choe, Sung ^{[11
]}

Wang, Hongfang ^{[11
]}

Zhang, Vickie ^{[11
]}

Dai, David ^{[11
]}

Fan, Bin ^{[11
]}

Yen, Katharine E. ^{[11
]}

Kapsalis, Stephanie M. ^{[11
]}

Hickman, Denice ^{[11
]}

Agresta, Samuel V. ^{[11
]}

Liu, Hua ^{[11
]}

Wu, Bin ^{[11
]}

Attar, Eyal C. ^{[11
]}

Kantarjian, Hagop M. ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[4] Inst Gustave Roussy, Villejuif, France

[5] Massachusetts Gen Hosp, Canc Ctr, Boston, MA USA

[6] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA

[7] City Hope Med Ctr, Duarte, CA USA

[8] Mayo Clin, Jacksonville, FL 32224 USA

[9] Dana Farber Canc Inst, Boston, MA 02115 USA

[10] Univ Texas Southwestern Med Ctr, Dallas, TX USA

[11] Agios Pharmaceut Inc, Cambridge, MA USA

来源：

BLOOD | 2018年 / 132卷

关键词：

D O I：

10.1182/blood-2018-99-111264

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

1812

引用

页数：3

共 50 条

[1] Ivosidenib (AG-120) Induced Durable Remissions and Transfusion Independence in Patients with IDH1-Mutant Untreated AML: Results from a Phase 1 Dose Escalation and Expansion Study
Roboz, Gail J.
DiNardo, Courtney D.
Stein, Eytan M.
de Botton, Stephane
Mims, Alice S.
Prince, Gabrielle T.
Altman, Jessica K.
Arellano, Martha L.
Donnellan, William B.
Erba, Harry P.
Mannis, Gabriel N.
Pollyea, Daniel A.
Stein, Anthony S.
Uy, Geoffrey L.
Watts, Justin M.
Fathi, Amir T.
Kantarjian, Hagop M.
Tallman, Martin S.
Choe, Sung
Dai, David
Fan, Bin
Wang, Hongfang
Zhang, Vickie
Yen, Katharine E.
Kapsalis, Stephanie M.
Hickman, Denice
Liu, Hua
Agresta, Samuel V.
Wu, Bin
Attar, Eyal C.
Stone, Richard M.
BLOOD, 2018, 132
[2] Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
Foran, James M.
DiNardo, Courtney D.
Watts, Justin M.
Stein, Eytan M.
De Botton, Stephane
Fathi, Amir T.
Prince, Gabrielle T.
Stein, Anthony
Stone, Richard M.
Patel, Prapti A.
Tallman, Martin S.
Choe, Sung
Wang, Hongfang
Zhang, Vickie
Fan, Bin
Yen, Katharine E.
Oluyadi, Abdulafeez
Winkler, Thomas
Hickman, Denice
Agresta, Samuel V.
Liu, Hua
Wu, Bin
Attar, Eyal C.
Kantarjian, Hagop M.
BLOOD, 2019, 134
[3] Ivosidenib (IVO; AG-120) in IDH1-Mutant Relapsed or Refractory Myelodysplastic Syndrome: Updated Results from a Phase 1 Study
DiNardo, Courtney D.
Foran, James M.
Watts, Justin M.
Stein, Eytan M.
De Botton, Stephane
Fathi, Amir T.
Prince, Gabrielle T.
Stein, Anthony S.
Stone, Richard M.
Patel, Prapti A.
Tallman, Martin S.
Choe, Sung
Wang, Hongfang
Zhang, Vickie
Dai, David
Fan, Bin
Yen, Katherine E.
Kapsalis, Stephanie K.
Hickman, Denice
Agresta, Samuel V.
Liu, Hua
Wu, Bin
Attar, Eyal C.
Kantarjian, Hagop M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S340 - S340
[4] Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study
DiNardo, Courtney D.
Foran, James M.
Watts, Justin M.
Stein, Eytan M.
de Botton, Stephane
Fathi, Amir T.
Prince, Gabrielle T.
Stein, Anthony S.
Stone, Richard M.
Patel, Prapti A.
Roboz, Gail J.
Arellano, Martha L.
Erba, Harry P.
Pigneux, Arnaud
Stuart, Robert K.
Thomas, Xavier
Uy, Geoffrey L.
Oluyadi, Abdulafeez
Lemieux, Ian R.
Liu, Hua
Wu, Bin
Winkler, Thomas
Garcia-Manero, Guillermo
Sallman, David A.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S321 - S321
[5] Ivosidenib (AG-120) in Mutant IDH1 AML and Advanced Hematologic Malignancies: Results of a Phase 1 Dose Escalation and Expansion Study
DiNardo, Courtney D.
De Botton, Stephane
Stein, Eytan M.
Roboz, Gail J.
Mims, Alice S.
Pollyea, Daniel A.
Swords, Ronan T.
Altman, Jessica K.
Collins, Robert H.
Mannis, Gabriel N.
Uy, Geoffrey L.
Donnellan, Will
Pigneux, Arnaud
Fathi, Amir T.
Stein, Anthony S.
Erba, Harry P.
Prince, Gabrielle T.
Foran, James M.
Traer, Elie
Stuart, Robert K.
Arellano, Martha L.
Slack, James L.
Sekeres, Mikkael A.
Yen, Katharine
Kapsalis, Stephanie M.
Liu, Hua
Goldwasser, Meredith
Agresta, Sam
Attar, Eyal C.
Tallman, Martin S.
Stone, Richard M.
Kantarjian, Hagop M.
BLOOD, 2017, 130
[6] Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment and results of a phase 1 dose-escalation and expansion substudy.
Sallman, David Andrew
Foran, James M.
Watts, Justin M.
Stein, Eytan
De Botton, Stephane
Fathi, Amir Tahmasb
Prince, Gabrielle T.
Stone, Richard M.
Patel, Prapti Arvind
Roboz, Gail J.
Arellano, Martha Lucia
Erba, Harry Paul
Pigneux, Arnaud
Baratam, Praneeth
Thomas, Xavier G.
Bai, Xiaofei
Kapsalis, Stephanie M.
Garcia-Manero, Guillermo
Dinardo, Courtney Denton
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[7] Ivosidenib (AG-120) in Mutant IDH1 Relapsed/Refractory Acute Myeloid Leukemia: Results of a Phase 1 Study
DiNardo, Courtney D.
Stein, Eytan M.
de Botton, Stephane
Roboz, Gail J.
Altman, Jessica K.
Mims, Alice S.
Swords, Ronan
Collins, Robert H.
Mannis, Gabriel N.
Pollyea, Daniel A.
Donnellan, Will
Fathi, Amir T.
Pigneux, Arnaud
Erba, Harry P.
Prince, Gabrielle T.
Stein, Anthony S.
Uy, Geoffrey L.
Foran, James M.
Traer, Elie
Stuart, Robert K.
Arellano, Martha L.
Slack, James L.
Sekeres, Mikkael A.
Willekens, Christophe
Choe, Sung
Wang, Hongfang
Zhang, Vickie
Yen, Katharine E.
Kapsalis, Stephanie M.
Yang, Hua
Dai, David
Fan, Bin
Goldwasser, Meredith
Liu, Hua
Agresta, Sam
Wu, Bin
Attar, Eyal C.
Tallman, Martin S.
Stone, Richard M.
Kantarjian, Hagop M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S204 - S205
[8] Population Pharmacokinetics of Ivosidenib (AG-120) in Patients with IDH1-Mutant Advanced Hematologic Malignancies
Le, Kha
Wada, Russ
Dai, David
Fan, Bin
Liu, Guowen
Liu, Hua
Attar, Eyal C.
Agresta, Samuel V.
Yang, Hua
BLOOD, 2018, 132
[9] Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome
DiNardo, Courtney D.
Roboz, Gail J.
Watts, Justin M.
Madanat, Yazan F.
Prince, Gabrielle T.
Baratam, Praneeth
de Botton, Stphane
Stein, Anthony
Foran, James M.
Arellano, Martha L.
Sallman, David A.
Hossain, Mohammad
Marchione, Dylan M.
Bai, Xiaofei
Patel, Prapti A.
Kapsalis, Stephanie M.
Garcia-Manero, Guillermo
Fathi, Amir T.
BLOOD ADVANCES, 2024, 8 (15) : 4209 - 4220
[10] Ivosidenib (IVO; AG-120) in mutant IDH1 relapsed/refractory acute myeloid leukemia (R/R AML): Results of a phase 1 study.
Pollyea, Daniel Aaron
Dinardo, Courtney Denton
de Botton, Stephane
Stein, Eytan
Roboz, Gail J.
Mims, Alice S.
Swords, Ronan T.
Altman, Jessica K.
Collins, Robert
Mannis, Gabriel N.
Uy, Geoffrey L.
Donnellan, William Bruce
Pigneux, Arnaud
Fathi, Amir Tahmasb
Liu, Hua
Wu, Bin
Attar, Eyal C.
Tallman, Martin S.
Stone, Richard M.
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →